REGNRegeneron Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc.17,593
Mkt Cap
$73.52BVolume
42,260.0052W High
$821.1152W Low
$476.49PE Ratio
17.09REGN Fundamentals
Price
$705.08Prev Close
$701.42Open
$703.0050D MA
$755.59Beta
0.63Avg. Volume
740,870.91EPS (Annual)
$41.48P/B
2.34Rev/Employee
$930,752.76$78,186.98
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Seizert Capital Partners LLC
Seizert Capital Partners LLC cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.1% in the 4th quarter, according to its most recent Form 13F filing with the...
MarketBeat·3h ago
Kornitzer Capital Management Inc. KS Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN
Kornitzer Capital Management Inc. KS acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,891 shares of the biopharmaceutical company's stock, valued...
MarketBeat·4h ago
Bellecapital International Ltd. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
Bellecapital International Ltd. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,109 shares of the bio...
MarketBeat·7h ago
PKO Investment Management Joint Stock Co Has $3.74 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
PKO Investment Management Joint Stock Co reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 56.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,850 shares of the biopharmace...
MarketBeat·1d ago
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twenty-six analysts that are currently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, sixte...
MarketBeat·1d ago
Del Sette Capital Management LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN
Del Sette Capital Management LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent filing with the Securities...
MarketBeat·2d ago
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·2d ago
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
read more...
Benzinga·3d ago
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $995.00
Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a "buy" rating in a report on Friday...
MarketBeat·3d ago
Wealthfront Advisers LLC Purchases 2,202 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Wealthfront Advisers LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,142 shares of the biopharmaceutical company's s...
MarketBeat·3d ago
<
1
2
...
>